A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Ravidasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Presidio Pharmaceuticals
- 21 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Oct 2014 New trial record